Skip to content

Medicines for Malaria Venture

Logo of the Medicines for Malaria Venture

One of the pillars of Medicine for Malaria Venture's (MMV) strategy 2024-2030 is to integrate anti-malarial development and access into climate change adaptation and mitigation. In mitigation, our strategy aims to contribute to mitigating climate change by minimizing the environmental and carbon footprint of the pharmaceutical development process. In adaptation, our ongoing work with local manufacturers, notably in Africa, is looking at ways to better forecast, deploy and pre-position this manufacturing capacity to respond to the needs of malaria-affected communities which are vulnerable to climate change. MMV has also worked closely with communities planning for and deploying seasonal malaria chemoprevention across 15 countries in the Sahel region for over a decade, and our proximity to national programmes which must anticipate and adapt their national malaria prevention campaigns in the face of shifting climate conditions has given us a deep appreciation for the potential role of tools like AI and climate modelling to help countries prepare for disruptions to their malaria prevention work in the future.

Supporting the following commitments:

  • Conduct climate change and health vulnerability and adaptation assessments (V&As) at population level and/or health care facility level.

Country experience:

MMV does not have physical presence, but activities through partnerships. E.g. MMV has had an advisory role from an antimalarial development and access perspective in the work of a modeler team in Senegal which is carrying out a study requested by the national malaria control programme to assess the impact of climate and options for adjusting the schedule of administration of seasonal malaria chemoprevention - commitment 1.


Site in English: 

Scroll to top